PhRMA member companies’ R&D investments reach record high of $91.1 billion in 2020

PhRMA member companies’ robust investment in research and development (R&D) has led to advances and discoveries that are transforming health care and our approach to treating patients for a broad range of chronic and rare conditions, as well as urgent new health challenges like COVID-19.